LAENNEC (Human Placenta Hydrolysate hPH) manufactured by Japan Bio Products Co., Ltd. which delivers unique technologies for effective extraction of variety of growth factors, cytokines and other physiologically active substances from the human placenta. For instance, HGF (hepatocyte growth factor) promotes the proliferation of hepatic parenchymal cells for recovery of a damaged liver.
GUARANTEE & EXPIRY DAY
100% original from the Japanese Japan Bio Products Co., Ltd. Expiry date up to 05.2026.
DESCRIPTION
Rich in bioactive substances such as amino acids and peptides, Laennec (human placenta hydrolysate) has been widely used to control various types of musculoskeletal pain. However, the effects of Laennec on tendon and ligament injuries are not clearly understood. This injectable human placenta extract is rich in beneficial growth factors that stimulate cellular renewal and have a hard-to-match detoxifying effect. The recommended treatment protocol consists of an initial phase during which the patient must be injected with it 2-3 days a week (1 vial of Laennec per session) for a period of one month. During the second stage of the therapy, patients undergo maintenance injection procedures performed by a registered practitioner every 10-15 days.
PACKAGE & DOSAGE
Laennec comes in ampoules for injection.
Active ingredients: human placenta hydrolyzate 112 mg.
Excipients: water for injection, sodium hydroxide or hydrochloric acid (for pH correction).
The standard adult dose is a 2 ml ampoule once daily for 10-20 days. According to symptoms, the dose can be increased to 2 or 3 times daily.
In chronic recurrent herpes and atopic dermatitis, the drug is administered intravenously by drip: 10 ml (560 mg of placenta hydrolyzate) of the drug (5 ampoules) are dissolved in 250-500 ml of a 5% dextrose solution or saline and injected through the cubital vein for 1.5-2 h. Injections are carried out 3 times a week with an interval of 2 days. The course of treatment is 10 injections.
In chronic liver diseases (steatohepatitis/alcoholic, metabolic and mixed etiology), the drug is administered intramuscularly at 2 ml per day (112 mg of placental hydrolyzate). Depending on the severity of the disease, the frequency of injections can be increased up to 2-3 times (6 ml) per day. The drug can be administered intravenously: 10 ml (560 mg of placental hydrolyzate) of the drug (5 ampoules) are dissolved in 250-500 ml of 5% dextrose solution or saline and injected through the cubital vein for 1.5-2 hours. Injections are carried out 2 times per week. The course of treatment is 2-3 weeks.
STORAGE
It is recommended to store the medicine in a dark place at a temperature not exceeding 25°C.
QUESTIONS
Ask us any questions about Laennec.
